
Roivant joins forces with Korea's iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs
→ Antibiotic resistance is a problem of epidemic proportions that should arguably entice a swarm of R&D dollars, but these drugs command relatively cheap prices and don’t last as long as, say, cancer drugs, which has incentivized Big Pharma to focus their attention elsewhere. However, a handful of small and big names are keeping the R&D engine hot. Vivek Ramaswamy’s Roivant Sciences on Monday announced it was taking a punt on Korean biotech iNtRON Bio, with a $667.5 million licensing agreement for SAL200, an experimental biologic for infectious diseases caused by antibiotic-resistant staphylococci. Roivant plans to initiate a Phase II trial testing the drug next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.